Loading
Breast Cancer Stage Ii / Breast Cancer Stage 0 / CONSYDER decision aid · Interventional Study
ClinicalTrials.gov · August 19, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a registered, currently recruiting interventional study evaluating CONSYDER, a web-based decision aid for surgical choice in young women with newly diagnosed breast cancer (stages 0–III). No outcome data have been published; the study measures decisional conflict and tool use via surveys and interviews over a 6-month post-surgical follow-up period.
Interventional, Randomized, Crossover, Open label, Health Services Research purpose. Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III; Female; age from 18 Years; to 44 Years. Intervention: CONSYDER decision aid. Compared with: Usual care — No Intervention. n = 800. 4 sites: United States.
This is a registered, currently recruiting interventional study evaluating CONSYDER, a web-based decision aid for surgical choice in young women with newly diagnosed breast cancer (stages 0–III). No outcome data have been published; the study measures decisional conflict and tool use via surveys and interviews over a 6-month post-surgical follow-up period.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
This is an ongoing interventional trial testing a decision-support tool in surgical decision-making for young breast cancer patients; no results are yet reported in this registry record.
As stated by the source record.
Quoted from the source exactly as published.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06275126). This is a study registration, not published results. Lead sponsor: Weill Medical College of Cornell University. Recruitment status: RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 800 participants (ESTIMATED). Conditions: Breast Cancer Stage 0, Breast Cancer Stage I, Breast Cancer Stage II, Breast Cancer Stage III. Interventions: OTHER: CONSYDER decision aid. Primary outcome measures: Pre-surgical decisional conflict as measured by the Decisional Conflict Scale (DCS) , pre-surgery; Use of CONSYDER pre-consult , pre-surgery. Brief summary: The goal of this study is to understand and improve the breast surgical decision-making process for young women newly diagnosed with breast cancer. As part of this study, the investigators will evaluate the impact and use a web-based tool called CONSYDER that is designed to provide useful information to young breast cancer patients. It is also meant to improve communication between young women and their surgeons with the purpose of helping patients make appropriate surgical decisions. Participants will complete surveys approximately within 1 week of the surgical consult and approximately 6 months after surgery. Patients who receive neoadjuvant chemotherapy will also be surveyed after the completion of neoadjuvant treatment but prior to surgery. Some patients will be invited for an interview after their surgery as part of the evaluation. A subset of patients/surgeons will also have their surgical consultation audio-recorded.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.